Silver Book Fact

Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections

Bressler N, Chang T, Fine J, Dolan C, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4). http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract

Reference

Title
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR
Publication
Ophthalmol
Publication Date
2010
Authors
Bressler N, Chang T, Fine J, Dolan C, et al.
Volume & Issue
Volume 117, Issue 4
Pages
747-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.  
  • Mobile Exam for DR
    Use of a mobile examination for DR screening in Finland decreased visual impairment by 86% in the covered area.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.